The World Health Organization has released its first guidance regarding the use of GLP-1 drugs in treating obesity. This condition impacts over a billion individuals worldwide. The WHO emphasizes that while medication can be helpful, it is not a standalone solution.
Obesity impacts more than 1 billion individuals globally and contributed to 3.7 million deaths in 2024.
The WHO's inaugural guideline concerning obesity care advocates for GLP-1 medications in the extended management of the condition in adults. Health tracking apps like Shotlee can help monitor progress alongside medication.
Track your medication journey
Join thousands using Shotlee to track GLP-1 medications.
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
The WHO cautions that medications alone are insufficient. Greater access, affordability, and enduring support systems are vital for addressing obesity effectively.
Original source: The Anniston Star
View original article →Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.
New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.
Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.
